Novavax is the fifth drugmaker to enter phase 3 trials for a COVID-19 vaccine in the U.S. Its vaccine uses more traditional technology than Pfizer and Moderna’s and doesn’t require ultra-cold storage, which makes it easier to distribute, according to The Hill.
The drugmaker is enrolling up to 30,000 people for the trial at 115 sites across the U.S. and Mexico. It’s already begun late-stage trials in the U.K. and had to delay the U.S. trial because of manufacturing issues.
“Trial sites were selected in locations where transmission rates are currently high to accelerate the accumulation of positive cases that could show efficacy,” Novavax said in a news release.
More articles on pharmacy:
Pfizer, Moderna testing COVID-19 vaccines against UK variant
Retailers in mad rush to hire, bring back pharmacists
FDA investigating allergic reactions to Pfizer-BioNTech COVID-19 vaccine
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
